CV Sciences operates two distinct divisions: pharmaceuticals and consumer products. These divisions are supported by our medical and scientific advisory board, and state-of-the art production facilities.

Press Releases

CV Sciences, Inc. Hosts Lunch Seminar at National University of Natural Medicine 2017 Medical Cannabis Conference

Company Enters its Second Year Sponsoring Continuing Education for University Students, Alumni, and Local Practitioners Interested in Learning More about Cannabis-Related Research and Methodologies

LAS VEGAS, NV–(Marketwired – July 25, 2017) – CV Sciences, Inc., (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), preeminent supplier and manufacturer of hemp-derived cannabidiol (CBD) oil bulk and consumer products, today announced that it will be exhibiting and presenting at the National University of Natural Medicine (NUNM)’s 2017 Medical Cannabis Conference in Academic Building Room 310 on July 29-30, 2017, in Portland, Oregon as Lead Sponsor.

NUNM conference attendees are invited to a very special lunch lecture on stress, adrenal health, and hemp-derived CBD, hosted by CV Sciences’ Medical Advisor and renowned naturopathic physician, Dr. Aimée Shunney, on July 30th, 2017 held from 12:30pm to 2pm. Dr. Shunney will provide an engaging review of the emerging evidence on the role of hemp-derived CBD and phytocannabinoids to support healthy adrenal function throughout life. Attendees will also discover the interactions of CBD and the human endocannabinoid system as it relates to human health, as well as the potential clinical applications for primary care, safety and plant-drug interaction data, and quality, sourcing, and dosing.

“As a proud alum from NUNM and a Medical Advisor to CV Sciences, I am honored and excited to have the opportunity to share my clinical experience with hemp-derived CBD at the NUNM Cannabis Conference. Being a naturopathic physician for 16 years, I have a passion for exploring new modalities in my treatment protocols to address stress resilience for day to day quality of life as well as chronic disease risk reduction,” Dr Shunney explains. “The addition of hemp-derived CBD to my toolbox has literally transformed my ability to help my patients manage the effects of stress, stabilize mood, and sleep better.”

Attendees are also encouraged to stop by the CV Sciences booth to learn more about its industry-leading supplement line, PlusCBD Oil™, where they can receive free samples, educational tools and meet with Dr. Shunney and the CV Sciences team.

ABOUT AIMÉE SHUNNEY, ND

Aimée Gould Shunney, Naturopathic Physician, is in private practice in Santa Cruz, California, where she blends conventional medical diagnosis and treatment with the use of natural therapeutics including dietary and lifestyle counseling, nutritional supplements, herbal medicine, and bio-identical hormones. Dr. Shunney specializes in women’s health, functional endocrinology, and family medicine. After graduating from NUNM in 2001, Dr. Shunney was in private practice in Brooklyn, NY and Greenwich, CT. In addition, she implemented and directed the Health Education and Wellness Program at Long Island College Hospital, also in Brooklyn, that served over 3000 people during her time there. She relocated to Santa Cruz in 2005. Dr. Shunney currently serves a Medical Advisor for CV Sciences and Nordic Naturals. Learn more by visiting http://www.drshunney.com.

About CV Sciences, Inc.

CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.

FORWARD-LOOKING DISCLAIMER

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

CONTACT INFORMATION:

Robert Haag
Managing Director
IRTH Communications
CVSI@irthcommunications.com
866-976-4784

Leave a Reply

Your email address will not be published. Required fields are marked *